What other gene rearrangements (ie, gene fusions) have recently been identified (such as ROS1, BRAF, RET) that are susceptible to targeted therapies? What are the current clinical implications for testing?

What other gene rearrangements (ie, gene fusions) have recently been identified (such as ROS1, BRAF, RET) that are susceptible to targeted therapies? What are the current clinical implications for testing?

What other gene rearrangements (ie, gene fusions) have recently been identified (such as ROS1, BRAF, RET) that are susceptible to targeted therapies? What are the current clinical implications for testing?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Nir Peled, MD, PhD, FCCP

Professor Nir Peled, MD, PhD, FCCP

Pulmonologist and Medical Oncologist
Thoracic Cancer Unit
Davidoff Cancer Center
Tiqwa, Israel